114 completed, 23 unknown, 22 terminated, 12 recruiting. 116 Phase 2, 63 Phase 1, 11 Phase 3, 7 Phase 4, 6 Not applicable.
Follow GM-CSF: new trials by email Literature Review of GM-CSF trials Research Report on GM-CSF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 60 | 2026-11-01 | 2026-10-16 |
| Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF - Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 42 | 2026-03-04 | 2026-04-03 |
| Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | Phase 1 | Recruiting | David Avigan | 30 | 2026-02-12 | 2026-05-05 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM DC/MM Fusion Vaccine, GM-CSF - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2026-01-30 | 2026-05-08 |
| Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF - Advanced Refractory Solid Tumors | Phase 2 | Not yet recruiting | Second Affiliated Hospital of Soochow University | 40 | 2025-12-27 | 2026-01-08 |
| Tebentafusp-tebn With LDT in Metastatic UM Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | Thomas Jefferson University | 109 | 2025-10-15 | 2026-07-21 |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2025-01-31 | 2026-05-07 |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan - Neuroblastoma | Phase 2 | Recruiting | New Approaches to Neuroblastoma Therapy Consortium | 62 | 2024-12-16 | 2026-07-20 |
| N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma DANYELZA, Sargramostim, Cytoxan - High-risk Neuroblastoma, Neuroblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2024-07-22 | 2026-08-28 |
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. Naxitamab - Neuroblastoma | Phase 4 | Not yet recruiting | SciClone Pharmaceuticals | 62 | 2023-10-31 | 2023-09-21 |
| The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy GM-CSF - GM-CSF | Phase 2 | Unknown | Sun Yat-sen University | 138 | 2023-09-15 | 2024-06-25 |
| Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma Naxitamab monotherapy, GM-CSF, Irinotecan - Neuroblastoma | Phase 2 | Recruiting | Sun Yat-Sen University Cancer Center | 120 | 2023-06-19 | 2025-06-17 |
| A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage colony-stimulating factor subcutaneous injection - Advanced Solid Tumor, Refractory Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 30 | 2023-06-16 | 2023-09-21 |
| Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor - Advanced Solid Tumor, Refractory Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-04-01 | 2023-03-30 |
| Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor - Carcinoma, Non-Small-Cell Lung, Carcinoma Breast | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 45 | 2022-10-30 | 2022-11-02 |
| Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors GM-CSF - Objective Response Rate | Phase 2 | Unknown | Xiangpan Li | 56 | 2022-10-01 | 2023-03-08 |
| PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF - Metastatic Solid Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 56 | 2022-09-01 | 2022-09-07 |
| ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab ERC1671, GM-CSF, Cyclophosphamide - Glioma, Malignant | Phase 2 | Unknown | Epitopoietic Research Corporation | 28 | 2022-07-01 | 2022-05-13 |
| GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS GM-CSF, Placebo - Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome | Phase 3 | Completed | Nationwide Children's Hospital | 141 | 2022-06-14 | 2026-04-09 |
| Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC hypofractionation Radiotherapy, sintilimab, GM-CSF - Colorectal Neoplasms | Phase 2 | Unknown | The First Affiliated Hospital of Xiamen University | 71 | 2022-03-25 | 2022-03-31 |
Showing 20 of 185. Sign in to see all of them.
Neuroblastoma (19) · Melanoma (18) · Breast Neoplasms (14) · Prostatic Neoplasms (14) · Leukemia (13) · Lymphoma (11) · Leukemia, Myeloid, Acute (10) · Multiple Myeloma (10) · Breast Neoplasms, Male (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Neoplasm Metastasis (5) · Osteosarcoma (5)
National Cancer Institute (NCI) (15) · M.D. Anderson Cancer Center (12) · Memorial Sloan Kettering Cancer Center (6) · Second Affiliated Hospital of Soochow University (6) · University of Washington (6) · Children's Oncology Group (5) · Mayo Clinic (5) · Sellas Life Sciences Group (4) · David Avigan (3) · Emory University (3) · Sir Run Run Shaw Hospital (3) · The Methodist Hospital Research Institute (3) · University of Wisconsin, Madison (3) · Beth Israel Deaconess Medical Center (2) · Epitopoietic Research Corporation (2)
United States (136) · China (24) · Germany (7) · Spain (7) · United Kingdom (7) · Australia (6) · Canada (6) · Netherlands (5) · Poland (5) · France (4) · Hungary (4) · Puerto Rico (4) · Russia (4) · Belgium (3) · Italy (3)
David Avigan, MD (3) · Robert J Amato, DO (3) · B. Smith (2) · Brian Kushner, MD (2) · Clive S. Zent, MD (2) · Issa F. Khouri, MD (2) · John Marshall (2) · Kunle Odunsi (2) · Mark W Hall, MD (2) · Mary Disis (2) · Robert O Dillman, MD (2) · Abby Maizel, MD, PhD (1) · Abby Maizel, MD,PhD (1) · Ahmad A. Tarhini, MD, MS (1) · Ajay K. Gopal, MD (1)
PMID 33986124, PMID 11359672, PMID 12506177, PMID 12620412, PMID 15337804, PMID 16116429, PMID 16123218, PMID 17252021, PMID 17299095, PMID 17312330, PMID 18470901, PMID 18623206, PMID 18809608, PMID 18833002, PMID 19538053, PMID 19546405, PMID 20576718, PMID 20625116, PMID 20879880, PMID 21525398, PMID 21690555, PMID 21926600, PMID 22270330, PMID 22282683, PMID 22495394, PMID 22822024, PMID 22853816, PMID 24723493, PMID 25126421, PMID 25454870, PMID 25688159, PMID 25865468, PMID 26014293, PMID 26096650, PMID 26291768, PMID 27190628, PMID 27720136, PMID 27879972, PMID 27999018, PMID 2827051, PMID 28358594, PMID 28851380, PMID 28923101, PMID 29386195, PMID 29510745, PMID 29863979, PMID 30817251, PMID 31171039, PMID 31401903, PMID 31406564
U10CA098543 (4), 2008 (2), P01CA015396 (2), P30CA015083 (2), P30CA022453 (2), P30CA043703 (2), P30CA051008 (2), 2009 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1), 2023 (1), P30CA006973 (1), P30CA015704 (1)